All Articles

New funds from RiverNorth will let investors bet on top private unicorns. But does this 'democratization' of venture capital come at too high a price?

A new survey reveals widespread employee frustration with workspaces is crippling productivity and RTO efforts. The fix isn't free, but the cost of inaction is far higher.

With a new FDA Fast Track designation, Satellos Bioscience aims to accelerate its unique muscle-regenerating drug for Duchenne, a strategy that could sidestep genetic limitations.

Dr. Mariusz Sapijaszko returns to lead the CDA amidst a crisis of access and a systemic shift to team-based care. His strategy is not to fight the tide, but to command it.

Flavors giant MANE partners with Kinaxis, betting on AI-driven supply chain orchestration to navigate global complexity and secure its next phase of growth.

As enterprise AI hits a data wall, OceanBase unveils its AI Database, a bold play to unify lake, database, and vector workloads into one trusted system.

Relmada Therapeutics joins the Russell 2000, a key validation that opens doors to new capital. But can its high-stakes pipeline deliver on this promise?

NexGold Mining secures C$10M via a savvy flow-through share placement, signaling deep investor trust and accelerating its quest for gold in Nova Scotia and Ontario.

LG's new 32-inch portable 4K screen aims to liberate your viewing experience. But is this high-tech, high-price hybrid a glimpse of the future or a niche luxury?

A recent Honor Flight for Puerto Rican veterans was more than a trip; it was a profound act of recognition. Behind the emotional journey lies a model of sustained investment.

Kite Realty Group's $300M note offering isn't just about debt. It's a masterclass in capital strategy, shareholder protection, and Sun Belt growth.

Farmmi Inc.'s $3M offering sent its stock plummeting 69%. Is this a desperate move for survival or a strategic play to fund its ambitious U.S. expansion?

With CEO Steven Pelton’s immediate departure, Aegis Brands faces a critical juncture. Can an interim committee stabilize the ship amid declining revenues?

Bullish secures key approval in Gibraltar for tokenized securities, a strategic move paired with its Equiniti acquisition to build a regulated, end-to-end digital asset ecosystem.

Ring Energy's entry into the Russell 3000 is more than a milestone; it's a testament to strategic discipline. What does this reveal about value creation?

Merck's new HIV drug, IDVYNSO™, gets a crucial boost via a public health deal, signaling a strategic play to reclaim ground in a multi-billion dollar market.

XPENG's new X-Mind framework moves beyond reactive systems, enabling vehicles to simulate the future and make safer, more human-like driving decisions.

Larimar Therapeutics is rewriting the rare disease playbook. Its BLA filing for nomlabofusp leverages a novel FDA-aligned endpoint, creating a de-risked path to market.

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

The insurer's new app aims to unify fragmented health records. Is this the future of member engagement, or another data privacy tightrope for consumers?